Leadless Pacemaker System for Arrhythmia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new type of pacemaker called the Aveir™ Dual-Chamber (DR) Leadless Pacemaker. The goal is to determine if this device is safe and effective for individuals needing help with heartbeat regulation due to arrhythmia (irregular heartbeat). As a single-arm study, all participants will receive the same treatment. This trial may suit those who require a dual-chamber pacemaker and do not already have certain types of pacemakers or defibrillators implanted. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research and potentially benefit from an innovative treatment option.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What prior data suggests that the Aveir DR Leadless Pacemaker System is safe?
Research has shown that the Aveir™ Dual-Chamber (DR) Leadless Pacemaker System is generally safe for people. Studies have found that this pacemaker can address heart rhythm problems without the typical issues of traditional pacemakers, such as wire complications and chest infections.
In one study, 99% of patients successfully received pacemaker implants. Another study found that safety goals were met after one year, consistent with results seen after three months. This consistent safety over time is reassuring.
Overall, the Aveir DR Leadless Pacemaker System appears well-tolerated, with evidence suggesting it is a safe choice for those needing a pacemaker.12345Why are researchers excited about this trial?
Unlike traditional pacemakers, which require leads to connect the device to the heart, the Aveir DR Leadless Pacemaker System is entirely self-contained and implanted directly into the heart. This innovative design eliminates the need for leads, which can sometimes cause complications such as infections or lead dislodgement. Researchers are excited about this treatment because it simplifies the implantation procedure, potentially reduces recovery time, and lowers the risk of long-term complications associated with lead-based systems.
What evidence suggests that the Aveir DR Leadless Pacemaker System is effective for arrhythmia?
Research shows that the Aveir DR Leadless Pacemaker System effectively treats irregular heartbeats. Studies have found that this pacemaker maintains a steady heart rhythm without traditional wires, reducing wire-related complications. One study found that the pacemaker provided reliable heart pacing and synchronized the heart's rhythm. Another study confirmed its safety and effectiveness for patients requiring heart pacing. Overall, the evidence supports its effectiveness in managing heart rhythm issues.13678
Who Is on the Research Team?
Nicole Harbert
Principal Investigator
Abbott
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a slow heart rate or other arrhythmias who need a pacemaker, can follow the study procedures, and have at least one year life expectancy. It's not for those with other active implants, existing pacing leads (except fragments), pregnant or nursing women, or anyone in another conflicting study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Implant Procedure
Participants undergo the implant procedure for the Aveir DR Leadless Pacemaker system
Initial Follow-up
Participants are monitored for safety and effectiveness at 1 month, 3 months, and 6 months post-implant
Extended Follow-up
Participants continue to be monitored every 6 months until study completion
What Are the Treatments Tested in This Trial?
Interventions
- Aveir DR Leadless Pacemaker System
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abbott Medical Devices
Lead Sponsor
Dr. Etahn Korngold
Abbott Medical Devices
Chief Medical Officer
Medical training at Harvard Medical School and Massachusetts General Hospital
Robert B. Ford
Abbott Medical Devices
Chief Executive Officer since 2020
Bachelor's degree from Boston College, MBA from UC Berkeley, Haas School of Business